Five-Year Evaluation of the PROA-NEN Pediatric Antimicrobial Stewardship Program in a Spanish Tertiary Hospital

被引:0
作者
Fernandez-Polo, Aurora [1 ]
Melendo-Perez, Susana [2 ]
Larrosa Escartin, Nieves [3 ,4 ]
Mendoza-Palomar, Natalia [2 ]
Antoinette Frick, Marie [2 ]
Soler-Palacin, Pere [2 ]
机构
[1] Hosp Infantil, Inst Recerca Vall dHebron, Pharm Dept, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain
[2] Hosp Infantil, Inst Recerca Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain
[3] Univ Autonoma Barcelona, Inst Recerca Vall dHebron, Microbiol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain
[4] Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERINFEC, Madrid 28029, Spain
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 06期
关键词
antimicrobial stewardship; drug resistance; bacterial infections; mycoses; tertiary care centers; pharmaceutical economics; INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE EPIDEMIOLOGY; ANTIBIOTIC STEWARDSHIP; POLICY STATEMENT; PREVALENCE; CHILDREN; QUALITY; AMERICA; IMPACT;
D O I
10.3390/antibiotics13060511
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Actions to reduce and optimize antimicrobial use are crucial in the management of infectious diseases to counteract the emergence of short- and long-term resistance. This is particularly important for pediatric patients due to the increasing incidence of serious infections caused by resistant bacteria in this population. The aim of this study was to evaluate the impact of a pediatric antimicrobial stewardship program (PROA-NEN) implemented in a Spanish tertiary hospital by assessing the use of systemic antimicrobials, clinical indicators, antimicrobial resistance, and costs. Methods: In this quasi-experimental, single-center study, we included pediatric patients (0-18 years) admitted to specialized pediatric medical and surgical units, as well as pediatric and neonatal intensive care units, from January 2015 to December 2019. The impact of the PROA-NEN program was assessed using process (consumption trends and prescription quality) and outcome indicators (clinical and microbiological). Antibiotic prescription quality was determined using quarterly point prevalence cross-sectional analyses. Results: Total antimicrobial consumption decreased during the initial three years of the PROA-NEN program, followed by a slight rebound in 2019. This decrease was particularly evident in intensive care and surgical units. Antibiotic use, according to the WHO Access, Watch and Reserve (AWaRe) classification, remained stable during the study period. The overall rate of appropriate prescription was 83.2%, with a significant increase over the study period. Clinical indicators did not substantially change over the study period. Direct antimicrobial expenses decreased by 27.3% from 2015 to 2019. Conclusions: The PROA-NEN program was associated with reduced antimicrobial consumption, improved appropriate use, and decreased costs without compromising clinical and/or microbiological outcomes in patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Agencia Espanola de Medicamentos y Productos Sanitarios, 2019, Plan Nacional Frente a la Resistencia a los Antibioticos 2019-2021
  • [2] Antibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children's Hospitals Varies Substantially from Adult Surveillance Data in Europe
    Anna Bielicki, Julia
    Lundin, Rebecca
    Sharland, Mike
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (07) : 734 - 741
  • [3] [Anonymous], 2019, Annual epidemiological report for 2016
  • [4] Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children
    Ara-Montojo, M. F.
    Escosa-Garcia, L.
    Alguacil-Guillen, M.
    Seara, N.
    Zozaya, C.
    Plaza, D.
    Schuffelmann-Gutierrez, C.
    de la Vega, A.
    Fernandez-Camblor, C.
    Ramos-Boluda, E.
    Romero-Gomez, M. P.
    Ruiz-Carrascoso, G.
    Losantos-Garcia, I
    Mellado-Pena, M. J.
    Gomez-Gil, R.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (01) : 220 - 225
  • [5] Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118
  • [6] Management of children with multidrug-resistant sepsis in low-income and middle-income countries
    Basmaci, Romain
    Bielicki, Julia
    Daniels, Ron
    Kissoon, Niranjan
    Ellis, Sally
    Balasegaram, Monica
    Sharland, Mike
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (01) : 8 - 10
  • [7] Neonatal and Pediatric Antimicrobial Stewardship Programs in Europe-Defining the Research Agenda
    Brett, Ana
    Bielicki, Julia
    Newland, Jason G.
    Rodrigues, Fernanda
    Schaad, Urs B.
    Sharland, Mike
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (12) : E456 - E465
  • [8] Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP
    Cercenado, Emilia
    Rodriguez-Bano, Jesus
    Alfonso, Jose Luis
    Calbo, Esther
    Escosa, Luis
    Fernandez-Polo, Aurora
    Garcia-Rodriguez, Julio
    Garnacho, Jose
    Gil-Navarro, Maria Victoria
    Grau, Santiago
    Gudiol, Carlota
    Horcajada, Juan Pablo
    Larrosa, Nieves
    Martinez, Carmen
    Molina, Jose
    Nuvials, Xavier
    Oliver, Antonio
    Pano-Pardo, Jose Ramon
    Perez-Rodriguez, Maria Teresa
    Ramirez, Paula
    Rey-Biel, Pedro
    Vidal, Pablo
    Retamar-Gentil, Pilar
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2023, 41 (04): : 238 - 242
  • [9] The use of continuous electronic prescribing data to infer trends in antimicrobial consumption and estimate the impact of stewardship interventions in hospitalized children
    Channon-Wells, S.
    Kwok, M.
    Booth, J.
    Bamford, A.
    Konstanty, P.
    Hatcher, J.
    Dixon, G.
    Diggle, P. J.
    Standing, J. F.
    Irwin, A. D.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (09) : 2464 - 2471
  • [10] de Salut D.G., 2018, Dipsit Legal: B 234462014